hlbscience
-
HLB Group Confirms Full Payment of USD 145 Million Investment from LMR PartnersBig Tech 2025. 11. 14. 15:55
HLB Group announced that UK-based global asset manager LMR Partners has fully paid its USD 145 million (KRW 206.9 billion) investment, comprising USD 140 million from HLB’s 42nd private BW issuance and USD 5 million from HLB Life Science’s overseas exchangeable bonds. IT Times: http://www.ittimes.com/news/articleView.html?idxno=81619 LMR Partners Completes Full $145 Million Funding for HLB Group..
-
HLB Science Merger with HLB Confirmed with 99% Shareholder ApprovalBig Tech 2025. 11. 13. 15:19
On November 13, HLB Science announced that its shareholders approved the merger with HLB at an extraordinary general meeting in Seoul, with 99% voting in favor. Under the agreement, HLB will remain the surviving company with a merger ratio of 1 to 0.0446318, and HLB Science will be dissolved. The unified company aims to combine HLB’s oncology expertise with HLB Science’s peptide-based discovery ..
-
HLB PEP and HLB Science Partner to Develop Antimicrobial and Antiviral PeptidesBig Tech 2025. 8. 4. 23:57
HLB PEP and HLB Science, two biotech affiliates of HLB Group, have signed a joint development agreement to co-develop next-generation peptide-based antimicrobial and antiviral therapeutics. The partnership focuses on advancing treatments for multidrug-resistant bacteria and viral infections, with lead candidates AGM-290 and AGM-380 targeting bacterial membranes and viral proteins. The collaborat..
-
HLB Science Completes Phase 1 Trial of New Antibiotic for Sepsis and SuperbugsBig Tech 2025. 7. 3. 01:48
HLB Science completed dosing in the Phase 1 clinical trials of its investigational antibiotic 'DD-S052P' for sepsis and superbug infections in both France and the United States. The company expects to receive the final Clinical Study Report (CSR) by the end of August. Read more: https://www.ittimes.com/news/articleView.html?idxno=79211 HLB Science Completes Phase 1 Trial of New Antibiotic for Se..